ATG 002

Drug Profile

ATG 002

Alternative Names: ATG-002

Latest Information Update: 06 Oct 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CoMentis
  • Class Small molecules
  • Mechanism of Action Angiogenesis inducing agents; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 07 Aug 2007 Discontinued - Phase-I/II for Diabetic foot ulcer in USA (Topical)
  • 21 Jun 2006 Athenagen has filed an IND with the US FDA for diabetic foot ulcers
  • 31 May 2006 Phase-I/II clinical trials in Diabetic foot ulcer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top